Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Hematologic Neoplasms

Hematologic Diseases

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Anti-Infective Agents

All Drugs and Chemicals

Antineoplastic Agents

Rifampin

Romidepsin

Anti-Bacterial Agents

Antibiotics, Antitubercular

Antitubercular Agents

Enzyme Inhibitors

Histone Deacetylase Inhibitors

Romidepsin 14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.

Rifampin 600 mg oral once daily on Days 4-8

14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.

Ken Takeshita, MD

The purpose of this study is to evaluate the effect and safety of multiple doses of rifampin on the pharmacokinetics of romidepsin after a single intravenous (IV) infusion.

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

A Phase I Open-label, 2-period Study to Evaluate the Influence of Multiple Oral Doses of Rifampin on the Single Dose Pharmacokinetics of Romidepsin in Subjects With Advanced Cancer

AUC0-t: area under the plasma concentration time-curve from Time 0 to the time of the last quantifiable concentration (Ct), calculated by linear trapezoidal method when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.

Individual and mean romidepsin plasma concentrations by treatment and scheduled time data were collected. AUC0-24: area under the plasma concentration time-curve from Time 0 to 24 hours, calculated by linear trapezoidal method when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.

AUC0-∞: area under the plasma concentration time-curve from Time 0 extrapolated to infinity, calculated as \[AUCt + Ct/λz\]. λz is the apparent terminal rate constant. No AUC extrapolation was performed with unreliable λz. If the percentage of AUC extrapolated is ≥ 25%, AUC0-∞ will not be reported.

Maximum observed plasma concentration (Cmax)was obtained directly from the observed concentration versus time data.

Time to maximum observed plasma concentration (Tmax) was obtained directly from the observed concentration versus time data.

The terminal elimination half-life (t1/2) in plasma, was calculated as \[(ln 2)/λz\]. This was only calculated when a reliable estimate for λz could be obtained.

The apparent total plasma clearance (CL) was calculated as \[Dose/AUC0-∞\] for Romidepsin alone and co-administered with rifampin plasma concentrations.

Apparent total volume of distribution (Vz) was calculated as \[(CL)/λz\] for Romidepsin and co-administered with Rifampin.

AEs were considered related if assessed by the Investigator as possibly, probably or definitely related to study drug. Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.

Celgene

Romidepsin 14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8 and Rifampin 600 mg oral once daily on Days 4-8.

Romidepsin Plus Rifampin

Romidepsin and Rifampin

Age, Continuous

Sex: Female, Male

White

Black or African American

Other

Race/Ethnicity, Customized

Hispanic or Latino

Not Hispanic or Latino

Unknown or Not Reported

United Kingdom

United States

Region of Enrollment

Height

Weight

Body Surface Area (BSA)

0 = Fully active

1 = Restricted in physical strenuous activity

2 = Ambulaotry but unable to work

3 = Limited Self-Care

4 = Completely Disabled

Eastern Cooperative Oncology Group (ECOG) Performance Status is used by doctors and researchers to assess how a patient's disease is progressing, assess how the disease affects the daily living activities of the patient and determine appropriate treatment and prognosis.

0 = Fully Active (Most Favorable Activity); 1 = Restricted activity but ambulatory; 2 = Ambulatory but unable to carry out work activities; 3 = Limited Self-Care; 4 = Completely Disabled, No self-care (Least Favorable Activity)

Eastern Cooperative Oncology Group Performance Status (ECOG)

Senior Manager, Clinical Trials Disclosure

Romidepsin 14 mg/m\^2 intravenous infused over 4 hours on Day 1 and Day 8.

Romidepsin Day 1

Romidepsin 14mg/m\^2 intravenous infused over 4 hours on Day 8. Rifampin 600mg oral once daily on Days 4-8.

Romidepsin and Rifampin Day 8

The PK population included all participants who received at least 1 dose of study drug and had evaluable PK profiles. The primary reason for study discontinuation for the 1 participant was due to withdrawal of consent.

Area Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)of Romidepsin

Romidepsin 14 mg/m\^2 intravenous infused over 4 hours on Day 1.

Rifampin 600 mg oral once daily on Days 4-8

Romidepsin 14 mg/m\^2 intravenous infused over 4 hours on Day 8. Rifampin 600 mg oral once daily on Days 4-8

Area Under the Plasma Concentration Time-curve From Time 0 to 24-hour (AUC0-24) for Romidepsin

Romidepsin 14 mg/m\^2 intravenous infused over 4 hours on Day 1

Romidepsin 14 mg/m\^2 intravenous infused over 4 hours on Day 8. Rifampin 600 mg oral once daily on Days 4-8.

The primary objective was to assess the influence of multiple doses of rifampin on the PK of romidepsin. The PK population included all participants who received at least 1 dose of study drug and had evaluable PK profiles. The primary reason for study discontinuation for the 1 participant was due to withdrawal of consent.

Area Under the Plasma Concentration Time-curve From Time Zero Extrapolated to Infinity (AUC0-∞).

Romidepsin 14 mg/m\^2 intravenous infused over 4 hours on Day 1.

Romidepsin 14 mg/m\^2 intravenous infused over 4 hours on Day 8. Rifampin 600mg oral once daily on Days 4-8

Maximum Observed Plasma Concentration (Cmax)of Romidepsin

Note: The median, median difference ("romidepsin + rifampin" minus "romidepsin") and 90% CI of the median difference are from Hodges-Lehmann Estimate. The P-value is from Wilcoxon signed-rank test.

Time to Maximum Observed Plasma Concentration (Tmax)

Estimate of the Terminal Elimination Half-life in Plasma (t1/2)

Clearance (CL): Apparent Total Plasma Clearance.

The PK population was to consist of all participants who received at least 1 dose of study drug and had evaluable PK profiles.

Apparent Total Volume of Distribution (Vz).

= > 1 TEAE

= > 1 TEAE related to any study drug

= > 1 TEAE related to Romidepsin

= > 1 TEAE related to Rifampin

= > 1 Serious TEAE

= > 1 Serious TEAE related to any drug

= > 1 Serious TEAE related to Romidepsin

= > 1 Serious TEAE related to Rifampin

= > 1 TEAE leading to discontinuation

= > 1 TEAE related discontinuation to any drug

= > 1 Romidepsin related TEAE discontinuation

= > 1 Rifampin related TEAE discontinuation

Participants who died

Romidepsin 14 mg/m\^2 intravenous infused over 4 hours on Days 1 and 8. Rifampin 600 mg oral once daily on Days 4-8

The safety population included all subjects who received at least 1 dose of study drug.

Spots Global Cancer Trial Database for Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial